Top Stories
The filing was supported by Phase I/II data from the single-arm REFOCUS trial, in which Lyrfigtu was associated with an objective response rate of 46%.
The software, shaped by input from the likes of Sanofi, GSK and Pfizer, lets pharma teams revisit a drug candidate's benefit-risk strategy as new trial results and other evidence emerge.
The round was led by S32 and included NVIDIA, Anthropic's Anthology Fund, and a dozen other investors.
The anti-FcRn antibody came up short in a Phase II study for patients with cutaneous lupus erythematosus, but development continues in a range of autoimmune diseases.
Approved in the EU as a maintenance treatment for people with asthma, Trixeo Aerosphere is seen as a key competitor to GSK's own fixed-dose triple combination therapy Trelegy Ellipta.
Conference News
BOSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Rezera Inc. (the “Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 t...
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immu...
Jordi Mones, MD, PhD, to present the first direct-to-Phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy in macular degenerationBenjamin Bakall, MD, PhD, to pre...
Presentation will highlight the ongoing Phase 1 dose-escalation study evaluating PLT012 in patients with advanced solid tumorsPLT012 targets CD36 to inhibit lipid uptake in tumor-associated immune cel...
Garching / Munich, September 23, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, toda...
